Highlights Newsletter 2 This newsletter presents you the following key sessions: Watch the video interview with Prof. W. Tjalma on Trastuzumab IV versus SC: A time, motion and cost assessment in a lean operating day care oncology unit Preliminary safety and efficacy results of pertuzumab in combination with trastuzumab and taxane therapy in patients with HER2-positive metastatic breast cancer in the PERUSE study BELLE-trial: Buparlisib in combination with fulvestrant improves progression-free survival in patients with HR-positive, HER2-negative locally advanced or metastatic breast cancer progressed on everolimus A sentinel lymph node biopsy is feasible and safe for patients treated with neoadjuvant chemotherapy for a large breast tumour and no clinical signs of the cancer in the axillary lymph nodes STEPAUT trial confirms BOLERO-2 data COLET study: Cobimetinib plus paclitaxel as first-line treatment in advanced triple-negative breast cancer